146 related articles for article (PubMed ID: 26429956)
1. Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.
Gungor H; Saleem A; Babar S; Dina R; El-Bahrawy MA; Curry E; Rama N; Chen M; Pickford E; Agarwal R; Blagden S; Carme S; Salinas C; Madison S; Krachey E; Santiago-Walker A; Smith DA; Morris SR; Stronach EA; Gabra H
J Nucl Med; 2015 Dec; 56(12):1828-35. PubMed ID: 26429956
[TBL] [Abstract][Full Text] [Related]
2. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
[TBL] [Abstract][Full Text] [Related]
3. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
4. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
5. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: a clinicopathological study.
Kaira K; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Naito T; Hayashi I; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
Eur J Radiol; 2012 Sep; 81(9):2423-9. PubMed ID: 22055682
[TBL] [Abstract][Full Text] [Related]
7. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
Ragon BK; Odenike O; Baer MR; Stock W; Borthakur G; Patel K; Han L; Chen H; Ma H; Joseph L; Zhao Y; Baggerly K; Konopleva M; Jain N
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):431-440.e13. PubMed ID: 31056348
[TBL] [Abstract][Full Text] [Related]
8. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW; Jacene H; Song D; Vilardell F; Messersmith WA; Laheru D; Wahl R; Endres C; Jimeno A; Pomper MG; Hidalgo M
J Clin Oncol; 2009 Jun; 27(16):2697-704. PubMed ID: 19380450
[TBL] [Abstract][Full Text] [Related]
9. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
10. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Liu JF; Gray KP; Wright AA; Campos S; Konstantinopoulos PA; Peralta A; MacNeill K; Morrissey S; Whalen C; Dillon D; Matulonis UA
Gynecol Oncol; 2019 Jul; 154(1):95-101. PubMed ID: 31118140
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT in monitoring response to treatment in gynecological malignancies.
Amit A; Person O; Keidar Z
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):17-22. PubMed ID: 23299090
[TBL] [Abstract][Full Text] [Related]
12. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Westin SN; Sill MW; Coleman RL; Waggoner S; Moore KN; Mathews CA; Martin LP; Modesitt SC; Lee S; Ju Z; Mills GB; Schilder RJ; Fracasso PM; Birrer MJ; Aghajanian C
Gynecol Oncol; 2019 Dec; 155(3):420-428. PubMed ID: 31623857
[TBL] [Abstract][Full Text] [Related]
13. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.
Quarles van Ufford HM; van Tinteren H; Stroobants SG; Riphagen II; Hoekstra OS
J Nucl Med; 2010 Oct; 51(10):1507-16. PubMed ID: 20847179
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts.
Dandekar M; Tseng JR; Gambhir SS
J Nucl Med; 2007 Apr; 48(4):602-7. PubMed ID: 17401098
[TBL] [Abstract][Full Text] [Related]
15. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
16. Early metabolic change in (18)F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients' survival: PEACH study.
Tanaka Y; Ueda Y; Egawa-Takata T; Matsuzaki S; Kobayashi E; Yoshino K; Enomoto T; Tatsumi M; Kimura T
Cancer Chemother Pharmacol; 2016 Jan; 77(1):121-6. PubMed ID: 26659584
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
Chen JL; Appelbaum DE; Kocherginsky M; Cowey CL; Rathmell WK; McDermott DF; Stadler WM
Cancer Med; 2013 Aug; 2(4):545-52. PubMed ID: 24156027
[TBL] [Abstract][Full Text] [Related]
18. In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imaging.
Rybczynska AA; de Bruyn M; Ramakrishnan NK; de Jong JR; Elsinga PH; Helfrich W; Dierckx RA; van Waarde A
J Nucl Med; 2013 Sep; 54(9):1613-20. PubMed ID: 23940303
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
Perumal M; Stronach EA; Gabra H; Aboagye EO
Mol Imaging Biol; 2012 Dec; 14(6):753-61. PubMed ID: 22484552
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
